Product Information
DEXMETHYLPHENIDATE ER 30 MG CP is a generic product labeled by Granules Pharmaceuticals Inc., priced at $1.5594 per EA under NDC 70010000901. Its NADAC has been published 295 times since Feb 10, 2021.
FDA first approved this application on Sep 9, 2020. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
30 mg/1
Manufacturer
Granules Pharmaceuticals Inc.NDC
70010000901
Classification
Generic
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
DEXMETHYLPHENIDATE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA213813FDA Approved
9/9/2020
TE Code
AB
On Market Since
12/1/2020
Pharmacological Classes
Price Statistics
The NADAC for DEXMETHYLPHENIDATE ER 30 MG CP has been published 295 times since Feb 10, 2021, and over the history we have for it it has declined 67.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.5594 per EA |
|---|---|
| All-time high | $4.7909 (Feb 10, 2021) |
| All-time low | $0.7499 (May 22, 2024) |
| 52-week high | $1.9363 |
| 52-week low | $1.4839 |
| Median price | $1.7320 |
| Average price | $1.7578 |
| Largest weekly change | +83.4% (Aug 18, 2021) |
| Weeks tracked | 295 |
| Tracking since | Feb 10, 2021 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the DEXMETHYLPHENIDATE HYDROCHLORIDE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Granules Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
DEXMETHYLPHENIDATE HYDROCHLORIDE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Central Nervous System Stimulant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DEXMETHYLPHENIDATE ER 30 MG CP?
The current National Average Drug Acquisition Cost (NADAC) for DEXMETHYLPHENIDATE ER 30 MG CP, manufactured by Granules Pharmaceuticals Inc., is $1.5594 per EA (NDC 70010000901), effective Sep 30, 2026.
How has the price of DEXMETHYLPHENIDATE ER 30 MG CP changed over time?
Over the history we have for it, the NADAC for DEXMETHYLPHENIDATE ER 30 MG CP has declined 67.5%. It has been tracked across 295 weekly CMS publications since Feb 10, 2021.
What are the highest and lowest recorded NADAC prices for DEXMETHYLPHENIDATE ER 30 MG CP?
Since Feb 10, 2021, the NADAC for DEXMETHYLPHENIDATE ER 30 MG CP has ranged from a low of $0.7499 (May 22, 2024) to a high of $4.7909 (Feb 10, 2021), with a median of $1.7320 per EA.
Are there cheaper alternatives to DEXMETHYLPHENIDATE ER 30 MG CP?
No other NADAC-published product currently shares the active ingredient and strength of DEXMETHYLPHENIDATE ER 30 MG CP in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures DEXMETHYLPHENIDATE ER 30 MG CP?
DEXMETHYLPHENIDATE ER 30 MG CP (NDC 70010000901) is labeled by Granules Pharmaceuticals Inc., and CMS classifies it as a generic product.